John Squires, the recently anointed director of the U.S. Patent and Trademark Office, has determined that a machine learning patent application met the standard for patent subject matter eligibility, an outcome that seems to bode well for ML-based patent applications going forward.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Avidity, Beone, Bicara, Lundbeck, Mannkind, Medincell, Revir, Teva.
Astellas Pharma Inc. reported Oct. 14 that its CLDN18.2-targeting monoclonal antibody, zolbetuximab (Vyloy), did not meet the primary endpoint of overall survival in the phase II Gleam trial of patients with advanced pancreatic cancer.
The importance of scalability, combination therapies, immunotherapies and speed in developing cancer drugs are paramount in creating a revolution in treating patients who often don’t have much hope, according to a panel of developers who spoke at the BioFuture conference in New York.
Two biopharma companies launched within the past year raised top amounts in series B financings for 2025, seeking to advance their therapeutic candidates for cardiovascular diseases and obesity.
RSS
